{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:58:55Z","timestamp":1766516335140,"version":"3.40.5"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Geriatric depression is challenging to treat owing to age-related changes in pharmacokinetics and comorbidities. Although renal insufficiency and multimorbidity are typical geriatric complications that cannot be completely separated from each other, no study has examined the influence of these factors on the serum concentrations of antidepressants. For the first time, we evaluated the effects of these factors in combination on the dose-corrected serum concentration (C\/D) of antidepressants in geriatric patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this retrospective study, data from 123 geriatric patients in a gerontopsychiatric day care unit at the University Hospital of W\u00fcrzburg were analyzed. Multiple linear regression analysis and analysis of variance with confounders were used to examine the associations between glomerular filtration rate (GFR) and stages of renal impairment and the C\/D of venlafaxine, mirtazapine, sertraline, and escitalopram corrected for multimorbidity, sex, lithium intake, and the number of triple whammy drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>GFR (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, \u00df = \u22120.070) was associated with the C\/D of the active moiety of venlafaxine (N = 32). GFR, multimorbidity, and sex were not associated with the C\/D of mirtazapine, escitalopram, or sertraline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>As the influence of sex may be less pronounced than that of decreasing GFR in terms of the C\/D of the active moiety of venlafaxine in geriatric patients, we recommend considering the GFR for dose adjustment rather than sex. In conclusion, even in patients with mild renal impairment, serum venlafaxine concentration should be monitored to prevent overdosing. Mirtazapine, sertraline, and escitalopram may be well-suited antidepressants for geriatric patients with renal function impairment stage 2\u20133 as well as multimorbidity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001285","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:00:12Z","timestamp":1732626012000},"page":"297-302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Serum Concentration of Antidepressant Drugs in Geriatric Day Care Patients With Renal Insufficiency and Multimorbidity"],"prefix":"10.1097","volume":"47","author":[{"given":"Sibylle","family":"Reber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra S.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-612X","authenticated-orcid":false,"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jagp.2016.03.009","article-title":"Depression and depression treatment in a population-based study of individuals over 60 years old without dementia","volume":"24","author":"Karlsson","year":"2016","journal-title":"Am J Geriatr Psychiatry"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0043-119417","article-title":"What characterizes depression in old age? Results from the Bruneck study","volume":"51","author":"Defrancesco","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00103-012-1455-x","article-title":"[Life years gained. Long-term trends in mortality by causes of death in Germany and in an international perspective]","volume":"55","author":"Doblhammer","year":"2012","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00391-016-1174-2","article-title":"Diagnostics and multimodal treatment of depression in old age: new developments","volume":"50","author":"Eschweiler","year":"2017","journal-title":"Z Gerontol Geriatr"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archpsyc.1996.01830040039008","article-title":"Recovery in geriatric depression","volume":"53","author":"Alexopoulos","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41398-019-0424-7","article-title":"Psychobiological factors of resilience and depression in late life","volume":"9","author":"Laird","year":"2019","journal-title":"Transl Psychiatry"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjopharm.2007.10.001","article-title":"Pharmacodynamics in older adults: a review","volume":"5","author":"Bowie","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab Rev"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/clpt.1994.95","article-title":"The effect of renal-disease on the disposition of venlafaxine","volume":"56","author":"Troy","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/02813432.2016.1153242","article-title":"The role of diseases, risk factors and symptoms in the definition of multimorbidity\u2014a systematic review","volume":"34","author":"Willadsen","year":"2016","journal-title":"Scand J Prim Health Care"},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11920-014-0492-6","article-title":"Depression and cardiovascular disease: an update on how course of illness may influence risk","volume":"16","author":"Fiedorowicz","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3233\/JAD-181099","article-title":"Examining the link between cardiovascular risk factors and neuropsychiatric symptoms in mild cognitive impairment and major depressive disorder in remission","volume":"67","author":"Fischer","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/STROKEAHA.111.630871","article-title":"Depression and risk of stroke a meta-analysis of prospective studies","volume":"43","author":"Dong","year":"2012","journal-title":"Stroke"},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.encep.2019.01.005","article-title":"D\u00e9pression et strat\u00e9gies de coping chez les sujets \u00e2g\u00e9s atteints de diab\u00e8te de type 2","volume":"45","author":"F\u00e9ki","year":"2019","journal-title":"L'enc\u00e9phale"},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1093\/ndt\/gfs295","article-title":"Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)","volume":"27","author":"Nagler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20250314","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000350094","article-title":"Molecular mechanisms of depression: perspectives on new treatment strategies","volume":"31","author":"Lang","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0006-3223(89)90080-2","article-title":"Chronicity and relapse in geriatric depression","volume":"26","author":"Alexopoulos","year":"1989","journal-title":"Biol Psychiatry"},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0043-119799","article-title":"[Late life depression - diagnosis, pathophysiology and therapeutic strategies]","volume":"86","author":"Dafsari","year":"2018","journal-title":"Fortschr Neurol Psychiatr"},{"key":"R21-20250314","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.psc.2013.08.006","article-title":"What is the role of medications in late life depression?","volume":"36","author":"Kok","year":"2013","journal-title":"Psychiatr Clin North Am"},{"key":"R22-20250314","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.3399\/bjgp19X701297","article-title":"Management of depression and referral of older people to psychological therapies: a systematic review of qualitative studies","volume":"69","author":"Frost","year":"2019","journal-title":"Br J Gen Pract"},{"key":"R23-20250314","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/a-1157-9433","article-title":"Drug-drug interactions between lithium and cardiovascular as well as anti-inflammatory drugs","volume":"53","author":"Scherf-Clavel","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"R24-20250314","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"R25-20250314","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0269881120936509","article-title":"Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine","volume":"34","author":"Scherf-Clavel","year":"2020","journal-title":"J Psychopharmacol"},{"key":"R26-20250314","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15761\/CBHC.1000103","article-title":"Prevalence and type of potential pharmacokinetic drug-drug interactions in old aged psychiatric patients","volume":"1","author":"Hefner","year":"2015","journal-title":"Contemp Behav Health Care"},{"key":"R27-20250314","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1399-5618.2005.00199.x","article-title":"Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice","volume":"7","author":"Wilting","year":"2005","journal-title":"Bipolar Disord"},{"key":"R28-20250314","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-019-02637-w","article-title":"Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study","volume":"75","author":"Scherf-Clavel","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 1","key":"R29-20250314","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/1520-6394(2000)12:1+<63::AID-DA8>3.0.CO;2-T","article-title":"Efficacy of venlafaxine in geriatric depression","volume":"12","author":"Staab","year":"2000","journal-title":"Depress Anxiety"},{"issue":"suppl 2","key":"R30-20250314","first-page":"S286","article-title":"Sertraline and mirtazapine as geriatric antidepressants","volume":"25","author":"Holland","year":"2013","journal-title":"Psychiatr Danub"},{"key":"R31-20250314","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-199605050-00007","article-title":"Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression","volume":"5","author":"Davis","year":"1996","journal-title":"CNS Drugs"},{"key":"R32-20250314","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00228-017-2219-1","article-title":"Antidepressant pharmacotherapy in old-age depression-a review and clinical approach","volume":"73","author":"Pruckner","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R33-20250314","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R34-20250314","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-012-0952-2","article-title":"Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions","volume":"120","author":"Unterecker","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"R35-20250314","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.psc.2013.08.004","article-title":"Assessment of the person with late-life depression","volume":"36","author":"Glover","year":"2013","journal-title":"Psychiatr Clin North Am"},{"key":"R36-20250314","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jad.2012.08.026","article-title":"Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials","volume":"145","author":"Boessen","year":"2013","journal-title":"J Affect Disord"},{"key":"R37-20250314","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0165-1781(85)90057-5","article-title":"The modified Hamilton rating scale for depression: reliability and validity","volume":"14","author":"Miller","year":"1985","journal-title":"Psychiatry Res"},{"key":"R38-20250314","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jclp.20213","article-title":"Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung","volume":"62","author":"Shafer","year":"2006","journal-title":"J Clin Psychol"},{"key":"R39-20250314","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/occmed\/kqv043","article-title":"The Hamilton rating scale for depression","volume":"65","author":"Sharp","year":"2015","journal-title":"Occup Med (Lond)"},{"key":"R40-20250314","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R41-20250314","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00108-017-0195-2","article-title":"Diagnosis and treatment of chronic kidney disease","volume":"58","author":"Girndt","year":"2017","journal-title":"Internist"},{"key":"R42-20250314","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ije\/dyt018","article-title":"Cohort profile: the Berlin aging study II (BASE-II)","volume":"43","author":"Bertram","year":"2014","journal-title":"Int J Epidemiol"},{"key":"R43-20250314","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0000000000001080","article-title":"Smoking is associated with lower dose-corrected serum concentrations of escitalopram","volume":"39","author":"Scherf-Clavel","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R44-20250314","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/YIC.0000000000000250","article-title":"Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2","volume":"34","author":"Scherf-Clavel","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"R45-20250314","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study","volume":"35","author":"Taurines","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R49-20250314","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"year":"2008","key":"R50-20250314","article-title":"Summary of product characteristics, labelling and package leaflet; Efexor depot"},{"key":"R51-20250314","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-1302-8108","article-title":"Dose-corrected serum concentrations and metabolite to parent compound ratios of venlafaxine and risperidone from childhood to old age","volume":"54","author":"Fekete","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"R52-20250314","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:02:09Z","timestamp":1741964529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001285","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"2024-10-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}